.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Covington
Boehringer Ingelheim
Cantor Fitzgerald
Merck
Fish and Richardson
Johnson and Johnson
US Department of Justice
Mallinckrodt
Colorcon

Generated: December 13, 2017

DrugPatentWatch Database Preview

CUBICIN RF Drug Profile

« Back to Dashboard

When do Cubicin Rf patents expire, and when can generic versions of Cubicin Rf launch?

Cubicin Rf is a drug marketed by Cubist Pharms Llc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-eight patent family members in nineteen countries and four supplementary protection certificates in three countries.

The generic ingredient in CUBICIN RF is daptomycin. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the daptomycin profile page.
Drug patent expirations by year for CUBICIN RF

Pharmacology for CUBICIN RF

Ingredient-typeLipopeptides
Drug ClassLipopeptide Antibacterial

Medical Subject Heading (MeSH) Categories for CUBICIN RF

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms LlcCUBICIN RFdaptomycinPOWDER;INTRAVENOUS021572-003Jul 6, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Cubist Pharms LlcCUBICIN RFdaptomycinPOWDER;INTRAVENOUS021572-003Jul 6, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cubist Pharms LlcCUBICIN RFdaptomycinPOWDER;INTRAVENOUS021572-003Jul 6, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CUBICIN RF

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,835,382Lipopeptide compositions and related methods► Subscribe
9,662,397Lipopeptide compositions and related methods► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CUBICIN RF

Country Document Number Estimated Expiration
Russian Federation2012126076► Subscribe
Argentina079127► Subscribe
Japan2017075186► Subscribe
Singapore10201407724Y► Subscribe
World Intellectual Property Organization (WIPO)2011063419► Subscribe
Dominican RepublicP2012000140► Subscribe
Israel219891► Subscribe
European Patent Office2504353► Subscribe
Taiwan201141506► Subscribe
Mexico2012005993► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CUBICIN RF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB06/024United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
/2006Austria► SubscribePRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
22/2006Austria► SubscribePRODUCT NAME: DAPTOMYCIN
C0022France► SubscribePRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Fish and Richardson
Cerilliant
Johnson and Johnson
Federal Trade Commission
Chubb
Covington
Dow
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot